Table 3.
Pharmacokinetic Parameters for Salvinorin-A for Each Group (1 and 2) and Experimental Session in which It Was Administered (Placebo+Salvinorin-A and Antagonist+Salvinorin-A)
| Group 1 (n=11) | ||||
|---|---|---|---|---|
| Parameter | Placebo+Salvinorin-A | Naltrexone+ Salvinorin-A | t(10) | P |
| Tmax (min) | 1.36 (0.50) | 1.36 (0.50) | 0.00 | NS |
| Cmax (ng/mL) | 31.28 (13.38) | 40.34 (36.95) | -1.06 | NS |
| AUC0-240 min (ng/mL·min) | 463.61 (132.77) | 436.76 (106.58) | 0.71 | NS |
| AUC0-∞ (ng/mL·min) | 487.36 (142.24) | 457.06 (113.82) | 0.76 | NS |
| t1/2λz (min) | 50.44 (14.79) | 56.96 (7.77) | -2.12 | NS |
| Cl/F (L/min) | 2.33 (1.17) | 2.32 (0.62) | 0.03 | NS |
| Vz/F (L) | 166.32 (77.47) | 188.80 (46.00) | -1.06 | NS |
| Group 2 (n=12) | ||||
| Parameter | Placebo+Salvinorin-A | Ketanserin +Salvinorin-A | t(11) | P |
| Tmax (min) | 1.50 (0.52) | 1.42 (0.51) | 0.432 | NS |
| Cmax (ng/mL) | 31.25 (15.4) | 50.04 (37.64) | -1.89 | NS |
| AUC0-240 min (ng/mL·min) | 358.29 (162.69) | 423.82 (215.71) | -0.90 | NS |
| AUC0-∞ (ng/mL·min) | 371.14 (168.91) | 440.40 (219.39) | 0.93 | NS |
| t1/2λz (min) | 49.21 (15.58) | 56.24 (16.80) | -1.28 | NS |
| Cl/F (L/min) | 3.32 (1.60) | 2.83 (1.51) | 0.95 | NS |
| Vz/F (L) | 237.08 (133.90) | 223.00 (100.75) | 0.41 | NS |
Abbreviations: Tmax: time taken to reach the maximum concentration; Cmax: maximum concentration; AUC0-240: area under the concentration-time curve from 0 to 240 min; AUC0-∞: area under the concentration-time curve from 0 to infinity; t1/2λz: terminal half-life; Cl/F: clearance; Vz/F: apparent volume of distribution.
Values indicate mean (SD). In group 1, values were calculated for 11 volunteers only. Pairwise comparisons were conducted using within-subjects Student’s t tests.